Lucas-Samuel S
Agence nationale de sécurité du médicament, 143-147, boulevard Anatole-France, 93285 Saint-Denis, France.
Transfus Clin Biol. 2013 May;20(2):221-4. doi: 10.1016/j.tracli.2013.02.006. Epub 2013 Mar 19.
The European regulation n(o) 1394/2007/CE published on the 13th of November 2007 defined and harmonized the European regulatory framework for advanced therapy medicinal products. It creates a specialized committee located at the European Medicine Agency, in charge of the assessment of these medicinal products. The consequences of this regulation are introduced in the French regulation by the law n(o) 2011-302 published on the 22nd of March 2011. It detailed notably the possibility for public establishments (except health establishments) and nonprofit organisms to create pharmaceutical establishments. This law defined also a specific category of advanced therapy medicinal products, which fall under the "hospital exemption" framework. The rules regarding the authorizations of the establishments able to prepare these types of medicinal products and the authorization of the products are defined by the n(o) 2012-1236 decree published on the 6th of November 2012.
2007年11月13日发布的欧洲法规n(o) 1394/2007/CE对先进治疗药品的欧洲监管框架进行了定义和协调。它设立了一个位于欧洲药品管理局的专门委员会,负责评估这些药品。该法规的影响通过2011年3月22日发布的法国法律n(o) 2011 - 302引入法国法规。它特别详细说明了公共机构(卫生机构除外)和非营利组织创建制药机构的可能性。该法律还定义了一类特定的先进治疗药品,它们属于“医院豁免”框架。关于能够制备这类药品的机构的授权规则以及产品的授权规则由2012年11月6日发布的n(o) 2012 - 1236号法令确定。